Virtual Library

Start Your Search

Illaa Smesseim



Author of

  • +

    P2.11 - Screening and Early Detection (ID 178)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Screening and Early Detection
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.11-36 - The Role of FDG-PET Scans in Pre-Invasive Endobronchial Lesions (Now Available) (ID 2010)

      10:15 - 18:15  |  Presenting Author(s): Illaa Smesseim

      • Abstract
      • Slides

      Background

      Pre-invasive endobronchial squamous lesions, especially high-grade lesions, may serve as risk markers for developing lung cancer. However, it remains difficult to determine whether individual lesions will progress to lung cancer. 18 fluorodeoxyglucose (18F-FDG)-positron emission tomography (PET) is currently used as a golden standard for staging patients with lung cancer and to monitor treatment response. The role of FDG-PET-scans in patients with pre-invasive lesions has not yet been established. In our study we report the outcome of surveillance of 40 subjects with pre-invasive endobronchial lesions and investigate the use of 18F-FDG-PET-scans as part of a surveillance program.

      Method

      We retrospectively selected patients with pre-invasive endobronchial lesions who underwent pre-treatment FDG-PET scans at the VU Medical Center Amsterdam between 1995 and 2016. Patients with signs of invasive carcinoma at baseline, as confirmed by histology, were excluded. Autofluorescence bronchoscopy (AFB) was used for tissue sampling. The minimum follow up period was three months and the group underwent close surveillance with repeated AFB. Outcomes included progression-free survival (PFS) and overall survival (OS).

      Result

      Among 40 included patients, 17 patients had a positive FDG-PET-scan at baseline of which 13 (76,5%) patients developed lung cancer during follow up. Twenty-three patients had a negative FDG-PET of which 6 (26,1%) developed lung cancer during follow-up. The FDG-PET-positive group had a median progression free survival of 5,0 months and the FDG-PET-negative group 33,0 months (p<0,0001, Figure 2). There was no significant difference in overall survival between both groups.

      figure 2.png

      Conclusion

      Our present work demonstrates that subjects with pre-invasive endobronchial lesions and a positive FDG-PET scan are at high risk to develop lung cancer. We reported a significantly longer progression free survival in patients with pre-invasive lesions with a negative FDG-PET scan. This suggests that FDG-PET scan can be used to select patients that require more radical cancer treatment.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.